Friday Feb 21
Just Released: "Celator Pharmaceuticals, Inc. (CLPM) -...
The company develops and distributes therapies for the treatment of cancer. Its products include CPX-351 Liposome injection, which is a liposomal formulation of a synergistic 5:1 molar ratio of cytarabine and daunorubicin, two agents used to treat hematologic malignancies and CPX-1 Liposome Injection is a liposomal formulation of a synergistic 1:1 ... (more)
Low-dose lenalidomide plus cytarabine induce complete remission that...
Patients aged 70 years with a World Health Organization diagnosis of AML , without isolated 5q abnormalities, were eligible.
Multivariate and subgroup analyses of a randomized, multinational,...
Compared with younger patients, older adults with acute myeloid leukemia generally have poorer survival outcomes and less benefit from clinical trials.
Celator Pharma: An Elegant Platform To Improve Chemo
Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap.